• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

    2018-12-07 06:21:40JingWangYizhuoZhaoQimingWangLiZhangJianhuaShiZhehaiWangYingChengJianxingHeYuankaiShiHaoYuYangZhaoWeiqiangChenYiLuoXiuwenWangKejunNanFaguangJinJianDongBaolanLiZhujunLiuBaohuiHanKaiLi
    Cancer Biology & Medicine 2018年4期

    Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He,Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin,Jian Dong, Baolan Li, Zhujun Liu, Baohui Han, Kai Li

    1Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China;2Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai 230030, China; 3Department of Medical Oncology,Henan Province Tumor Hospital, Zhengzhou 450008, China; 4Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100730 China; 5Department of Medical Oncology, Linyi Cancer Hospital, Linyi 276001, China;6Department of Internal Medicine, Shandong Cancer Hospital, Jinan 250117, China; 7Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun 130012, China; 8Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; 9Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China; 10Department of Biostatistics, School of Public Health, Nanjing Medical University,Nanjing 210029, China; 11Department of Respiratory Medicine, Lanzhou Military General Hospital, Lanzhou 730050, China;12Department of Head and Neck Oncology, Hunan Cancer Hospital, Changsha 220633, China; 13Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan 250000, China; 14Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; 15Department of Respiratory and Critical Diseases, Tang Du Hospital, Xi'an 710038, China; 16Department of Oncology, Yunnan Cancer Hospital, Kunming 650032, China; 17General Department, Capital Medical University Beijing Chest Hospital, Beijing 101149, China

    ABSTRACT Objective: Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and c-MET; therefore, it exhibits both antitumor and anti-angiogenetic activities. A phase III trial has shown that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC), who presented with progressive disease or intolerance after standard chemotherapy. This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods: Data were collected from March 2015 to January 2017 from a randomized, double-blind, placebo-controlled,multicenter, phase III trial of anlotinib (ALTER0303). A total of 437 patients were enrolled and randomly allocated (2:1) to the anlotinib and placebo groups. Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS. Cox proportional hazards model was adopted for multivariate prognostic analysis.Results: Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS. Meanwhile, elevated thyroid-stimulating hormone, blood glucose, and triglyceride levels; hypertension; and hand–foot syndrome were independent protective factors of PFS. High posttherapeutic peripheral blood granulocyte/lymphocyte ratio, an Eastern Cooperative Oncology Group (ECOG) score ≥ 2, and the sum of the maximal target lesion length at baseline were independent risk factors of OS, and hypertriglyceridemia was an independent protective factor of OS.Conclusions: This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC, and the baseline characteristics of the therapeutically dominant populations were then identified.

    KEYWORDS Non-small cell lung cancer; anlotinib; third- or further-line therapy; prognostic factor analysis

    Introduction

    Non-small cell lung cancer (NSCLC) accounted for the highest morbidity and mortality rates among all other malignancies in recent years. Patients who received chemotherapy have a median survival of < 1 year, and those with driver gene mutations who receive targeted therapies also developed resistance after 1 year of treatment. The National Comprehensive Cancer Network guidelines provided regulations only for the first- and second-line regimens. Therefore, the primary focus of research is to help patients who are resistant to third- or further-line regimens recover and to lengthen their survival. Phase II1and III trials of the novel vascular-targeting agent anlotinib have shown that progression-free survival (PFS) and overall survival (OS)significantly improved in the anlotinib group than in the placebo group. However, this conclusion was only based on the general data of the patients. Thus, we evaluated the major factors that affected both the PFS and OS of the patients from the phase III trial with the hope of determining the therapeutically dominant populations and discovering an optimal therapeutic regimen for individuals with advanced refractory NSCLC.

    Materials and methods

    General data

    Between March 2015 and August 2016, 437 patients were enrolled from 31 research centers in China, and the data of the patients from March 2015 to January 2017 were collected.The major inclusion criteria were as follows: 1) patients who were pathologically diagnosed with stage III B/IV advanced NSCLC and had measurable nidus; 2) those who have progressive disease after receiving at least two standard systematic chemotherapeutic regimens or those who could not tolerate the toxicity of these treatments; 3) those who were negative for epidermal growth factor receptor (EGFR)and anaplastic lymphoma kinase (ALK) and can provide detectable specimens from tumor tissues or the hydrothorax for gene detection before participating in the study or those who were positive for EGFR and ALK and presented with progressive disease (PD) or intolerable adverse effects after treatment with relative targeted drugs; and 4) those with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0–1 points. All patients must sign the informed consent form prior to enrollment. The present trial was approved by the corresponding ethics committees of our institution and is registered in ClinicalTrials.gov (registration number: NCT02388919).

    Methods of treatment

    Patients were randomized to receive anlotinib or placebo in a 2 : 1 ratio. The medication was administered from days 1 to 14 in a 21-day cycle, and the initial dose of anlotinib was 12 mg oral administered once daily.

    Efficacy evaluation

    Objective efficacy measures were evaluated using the guidelines of the response evaluation criteria in solid tumors version 1.1.

    OS was defined as the duration between randomization and death from any cause. For patients who were considered lost to follow-up, the date of the last follow-up visit was calculated equally as the date of death.

    PFS was defined as the duration between randomization and objective tumor progression or death.

    For patients who had complete response (CR) or partial response (PR) and stable disease (SD) based on the efficacy evaluation, tumor nidi should be re-examined 4 and 6–8 weeks after the initial efficacy evaluation to identify the efficacy until disease progression (DP).

    Disease control rate was defined as the percentage of patients who can be evaluated and achieved CR, PR, and SD for at least 4 weeks.

    Record of adverse events

    Patients were regularly followed-up as per the trial protocol,and each observation index was recorded accordingly.Adverse events were assessed on the basis of the guidelines of the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0), and the most severe post-treatment adverse events in each therapeutic cycle were statistically analyzed.

    Statistical analysis

    All analyses were performed using the SAS 9.4 software (SAS Institute Inc., Cary, NC, the USA). Demographic data and baseline disease characteristics were presented as categorical variables. Univariate and multivariate Cox proportional hazards models were adopted to analyze the influential factors associated with PFS and OS. To establish the final model, a list of potential variables were firstly provided based on prior information regarding their clinical relevance, and the best subset method was then utilized to select the final model according to Chi-square statistics and clinical relevance. Variables that showed significance in the multivariate analysis were stratified, whereas the median OS or PFS were reported. Parameters with obvious clinical reference values, such as blood cholesterol and low-density lipoprotein (LDL) cholesterol level, were classified based on clinical reference values; meanwhile, parameters without obvious clinical reference values, such as pre-randomization maximal target lesion length and post-treatment granulocyte/lymphocyte ratio, were grouped using the cutoff values that were calculated using the receiver operating characteristic (ROC) curves. Cutoff values were obtained using survival status (dead or alive) at the end of follow-up and were considered as outcome variables. The value of the predictive variable with maximal sensitivity + sepecificity-1 was selected as the cutoff point. The between-group comparisons of OS and PFS were analyzed using t-test. For all analyses, a P value < 0.05 was considered statistically significant.

    Results

    Baseline data and efficacy

    In the present study, 437 and 377 patients were included in the full analysis set (FAS) and per protocol set (PPS),respectively, and 256 and 121 patients were classified into the anlotinib and placebo groups, respectively.

    By the end of the follow-up period (January 06, 2017) with a median follow-up period of 9.24 months for the anlotinib group and 7.33 months for the placebo group, the median PFS were 5.37 months [95% confidence interval (CI):4.40–5.63] for the anlotinib group and 1.40 months (95% CI:1.07–1.50) for the placebo group, which indicated statistically significant differences (P < 0.0001). Compared to the placebo group, the anlotinib group had an extended duration for the control of advanced NSCLC by 3.97 months and a lower risk for DP by 75%, which indicated statistically significant differences [hazard ratio (HR) = 0.25, 95% CI: 0.19–0.31, P <0.0001]. The OS were 9.63 months (95% CI: 8.17–10.60 ) and 6.30 months (95% CI: 5.00–8.10) in the anlotinib and placebo groups, respectively. Compared to that of the placebo group, the median OS of the anlotinib group improved by 3.33 months and their risk for mortality decreased by 32%. This result showed statistically significant differences (HR = 0.68, 95% CI: 0.54–0.87, P = 0.0018). In addition, after the data cutoff, we continued the follow-up for OS until May 2017, and further survival analysis showed a similar result. That is, a median OS of 9.60 months (95% CI:8.4–10.6) was obtained, and it was significantly (P = 0.0018)longer in the anlotinib group than in the placebo group with an improvement of 3.30 months. The baseline data of the 256 patients from the anlotinib group are listed in Table 1.

    Table 1 Clinicopathological data of 256 patients in the anlotinib group

    Univariate and multivariate analyses of efficacy

    Based on the primary observation parameters of the current trial and previous reports, we preliminarily selected 43 variables that might affect prognosis, and Kaplan–Meier univariate analysis and log-rank test were then conducted to assess the correlations between the variables and PFS or OS.The factors were categorized as follows: 1) patient factors,including sex, age, ECOG score at the end of the medication,blood granulocyte/lymphocyte ratio, changes in laboratory parameters before and after treatment, and occurrence of the most severe adverse events; 2) therapeutic factors, such as pre-randomization lines and duration of treatment and content of therapeutic regimens; and 3) tumor factors, such as sum of pre-randomized maximal target lesion length,clinical stage, pathological type, etc.

    Since the pre-randomization ECOG score of the trial was limited between 0 and 1 point and the post-treatment body performance of some patients worsened, which resulted in a higher ECOG score of 0–3 points in the univariate analysis,the patients were stratified into 0–1-point subgroup and 2–3-point subgroup. The cutoff value for the stratification of age was 60 years. Adverse events were defined on the basis of the definitions of CTCAE 4.0 (hand–foot syndrome, oral mucositis, and rash), and hypertension was defined as blood pressure ≥ 140/90 mmHg.

    Classification of the cutoff values of the laboratory parameters was based on their respective clinical reference values: hypertriglyceridemia was defined as a triglyceride level > 1.7 mmol/L, hypercholesterolemia was defined as cholesterol level > 5.17 mmol/L, elevated alkaline phosphatase (ALP) level was defined as an ALP level> 135 U/L, hyperglycemia was defined as blood sugar level> 5.9 mmol/L, hypomagnesemia was defined as blood magnesium level < 0.66 mmol/L, hypocalcemia was defined as serum calcium level < 2.10 mmol/L, hyponatremia was defined as blood sodium level <137 mmol/L, hyper-lowdensity lipoproteinemia was defined as lipoprotein level> 3.1 mmol/L, elevated thyroid-stimulating hormone (TSH)was defined as TSH level > 4.85 mIU/L, and prolonged QT interval on electrocardiogram (ECG) was defined as QT interval > 480 ms.

    For variables without a reference value, the ROC curves were used to analyze and determine the cutoff values with significant differences in OS, which is the primary endpoint of the trial. The cutoff value of pre-randomization maximal target lesion length was 72 mm, the sensitivity was 0.5283,the specificity was 0.7368, and the area under the curve was 0.6600. The cutoff value of post-treatment granulocyte/lymphocyte ratio was 3.10, the sensitivity was 0.6689, the specificity was 0.6989, and the area under the curve was 0.7089.

    Factors with statistically significant differences in the univariate analysis are listed in Table 2. However, variables without statistically significant correlations with PFS or OS are not shown.

    The SAS statistical software was utilized to select 15 combinations of variables using the fitting curve. The Cox model was then used to analyze the combination of variables,and results showed that the following variables had statistically significant differences (Table 3). However, the variables without statistically significant correlations with PFS or OS are not shown.

    Results of the multivariate analysis indicated that high post-treatment granulocyte/lymphocyte ratio and elevated ALP levels were considered independent risk factors of PFS,whereas hypertension, hand–foot syndrome (hand–foot skin reaction), hyperglycemia, hypertriglyceridemia, and elevated TSH levels were independent protective factors of PFS. Posttreatment ECOG score ≥ 2, high post-treatment peripheral blood granulocyte/lymphocyte ratio, and the sum of prerandomization maximal target lesion length were considered independent risk factors of OS, whereas hypertriglyceridemia was an independent protective factor of OS.

    To further evaluate the clinical significance of the cutoff values, stratified median PFS and OS were reported for each variable, which was statistically significant in the multivariate model according to these cutoff values(Table 4).

    Discussion

    Anlotinib is a self-developed multitargeted inhibitor designed to inhibit vascular endothelial growth factor receptor-2(VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor-1 (FGFR1), FGFR2, FGFR3, platelet-derived growth factor receptor-α (PDGFRα), PDGFRβ, c-KIT, c-Met, and EGFR in China2,3. Compared with similar target agents, such as sorafenib4, anlotinib targets the tumor vascular microenvironment and the responsible genes and signaling pathways associated with malignant biological behaviors,such as cancer cell growth, invasion, and metastasis.Therefore, it is considered to be a multitargeted, dualdimension, comprehensive anti-tumor drug that can control tumor resistance after a single chemotherapy or targeted drug treatment. In this trial, anlotinib was used in patients with advanced NSCLC who developed resistance after at least two therapeutic regimens. Results revealed a median PFS of 5.37 months and a median OS of 9.63 months, which lower therisks for DP by 75% (HR = 0.25, 95% CI: 0.19–0.31, P <0.0001) and 32% (HR = 0.68, 95% CI: 0.54–0.87, P =0.0018), respectively, compared to the placebo group. The PFS and OS of patients with advanced NSCLC (squamous cell carcinoma and adenocarcinoma) receiving classic second-line chemotherapeutic regimens are approximately 2.5 and 7 months, respectively5. Patients with adenocarcinoma who received second-line therapies based on pemetrexed had a median OS of 8.3 months6, whereas patients with adenocarcinoma who are taking tyrosine kinase inhibitor (TKI; Tarceva) as the second-line therapy had a median OS of 7.8 months7. However, data about the efficacy of third-line therapy that is supported by class II evidence or higher recommendations are still limited. In this trial, we used anlotinib as the third-line salvage regimen for patients who are resistant to treatment or those who cannot tolerate toxicities, and higher PFS and OS rates were observed in patients receiving these regimens than in those receiving

    previous standard second-line regimens. This might be due to the simultaneous inhibition of tumor and its angiogenesis and blockage of multiple key receptors, which effectively prevented tumor growth-related signaling. However, all enrolled patients who presented with advance cancer and refractory lung malignancies (including squamous cell cancer, adenocarcinoma, and large cell carcinoma but not limited to adenocarcinoma only) were significantly resistant to all the drugs compared with those with tumors who were receiving second- and inferior-line therapies. Hence, we conducted a stratified analysis to assess the factors that affect efficacy to determine therapeutically dominant populations and prevent the use of ineffective medications.

    Table 2 Results of the prognostic factor analysis of patients from the anlotinib group (univariate analysis)

    Table 3 Results of the prognostic factor analysis of patients in the anlotinib group (multivariate analysis)

    Results of the univariate analysis showed that 13 factors affected PFS, and they were primarily patient factors and adverse events (see table 2). No therapeutic factors significantly affected PFS. A total of 11 factors affect OS, and seven factors affected PFS. They were patient factors and tumor factors (Table 2), no therapeutic factors were involved. Based on the abovementioned results and previous reports, several parameters that affect the prognosis were introduced into the multivariate Cox model. The results showed that the post-treatment adverse events of hypertension and hand–foot syndrome, blood glucose level >5.9 mmol/L, triglyceride level > 1.7 mmol/L, and TSH level >4.85 mmol/L were considered independent protective factors of OS, whereas post-treatment granulocyte/lymphocyte ratio> 3.10 and ALP level > 135 U/L were considered independent risk factors of PFS. Post-treatment triglyceride level > 1.7 mmol/L was an independent protective factor for OS,whereas a post-treatment ECOG score of 2–3, post-treatment granulocyte/lymphocyte ratio > 3.10, and maximal target lesion length> 72 mm were independent risk factors for OS. To assess the practical cutoff values clinically, we adopted the ROC curve to analyze the cutoff values showing the most significant differences in PFS and OS. After comparing with the reference values used for clinical practice, the cutoff values presenting the near coincidence in each normal upper laboratory indexes and changes in blood pressure were almost similar to the normal upper limits of the corresponding clinical reference ranges. Therefore, the cutoff values of the factors in the current study, which were estimated via univariate and multivariate analyses, are considered independent factors of PFS or OS, and they should indicate clinical significance. During the univariate and multivariate analyses, we also directly selected the upper limits of the normal clinical reference ranges as the cutoff values for comparisons among populations with different PFS and OS for analysis. For measurement data other than clinical laboratory parameters and without a normal reference range, such as pre-randomization maximal target lesion length and post-treatment granulocyte/lymphocyte ratio, the abovementioned ROC curve analysis was adopted to determine the cutoff values presenting the most significant differences in PFS or OS. To re-confirm the power of the parameters identified via multivariate analysis in predicting PFS or OS, we further divided the groups based on the cutoff values of each index, and the PFS and OS of the subgroups were calculated. The results validated that the differences in PFS or OS between the two subgroups were statistically significant. Therefore, selection of the abovementioned cutoff values was considered reasonable.

    Based on the results, the previous treatment has not been considered an independent factor. Previously reported factors that correlated with the development of tumor resistance (pre-treatment lines and types of treatment)showed no statistical significance in the univariate or multivariate analysis. Traditionally, it was believed that increased chemotherapeutic line triggered multidrug resistance (MDR) in the tumor cells6, resulting in resistance to multiple chemotherapy drugs. Therefore, the efficacy of the second-line regimen was considered to be inferior to the first-line regimen. EGFR-TKIs can also trigger T790 mutation and c-Met gene amplification, resulting in resistance to first-generation drugs8,9. However, results of the current study showed that the abovementioned factors did not affect the prognosis after anlotinib treatment. This was probably attributable to the fact that anlotinib has mechanisms of action that are completely independent of the previous therapeutic mechanisms that caused changes in molecules that are susceptible to drug resistance. That is, its efficacy was not affected by MDR induced by chemotherapy,and it still remained effective for c-Met gene amplification2induced by EGFR-TKI. Theoretically, increased therapeutic types and lines increased gene changes, thus indicating the possibility of resistance to any novel drug. However, our present study has not investigated the correlation between the gene mutation load10induced by different previous therapeutic lines and the efficacy of anlotinib or any molecular mechanisms that may induce resistance to anlotinib. Nevertheless, a pre-treatment total tumor load(sum of pre-randomization maximal target lesion length) >72 mm predicted poor PFS and OS in the univariate analysis and poor OS in the multivariate analysis, and this result still indicated that the efficacy of anlotinib may be suboptimal in larger tumors with greater heterogeneity and mutation load.Therefore, efforts should be made to promote anlotinib from third-line therapy to second- or first-line therapy for thetreatment of early tumors.

    Table 4 PFS and OS of each variable from the subgroups were divided on the basis of the cutoff values

    It was noteworthy that factors from the multivariate analysis caused changes in the body and metabolism of patients, and the resultant adverse events (up to seven events,such as post-treatment ECOG score as well as hypertension,hand–foot syndrome, and high blood glucose, triglyceride,TSH, and ALP levels, observed during the trial period)predominately affected efficacy and prognosis. This phenomenon indicated that multiple targets and broad signaling pathways covered by anlotinib could help overcome the acquired resistance induced by previous few-line treatments. However, compared to the mono-target agents, it may cause more adverse reactions in patients and interact with their internal environments. Thus, the level of efficacy of anlotinib was primarily dependent on the individual physical characteristics of the patients.

    Similar to EGFR-TKIs11, treatment with anlotinib also resulted in hand–foot syndrome, which was considered to be a predictor of good PFS. Meanwhile, similar to antiangiogenic targeting agents12, anlotinib caused hypertension and prolonged QT intervals, with the former considered a good predictor of PFS. From the perspective of adverse events,although they have been proven tolerable and transient,anlotinib simultaneously functioned as an antiangiogenic targeting and EGFR-TKI agent.

    In this study, post-treatment granulocyte/lymphocyte ratio has been considered a risk factor of both PFS and OS; hence,it deserves special attention. Studies conducted in China and other countries have shown that the tumor-free survival rate was shorter in patients with abnormally increased peripheral blood granulocyte levels during relapse after lung surgery than in patients with normal levels. Hence, the concept of“tumor-related leukocytosis” has been proposed13, which is a syndrome that occurs due to the absence of immune function and lack of lymphocytes. Sequential studies have further revealed that the patients’ percentage of CD8+ T cells was usually low, the CD4+/CD8+ T-cell ratio was high, and OS was short14. Although no specific immune-related parameters were detected in this trial, our current results strongly suggested that the efficacy of anlotinib was probably correlated with the post-treatment immune function status and response of the patient, which further indicated the need for special attention to the changes in immune parameters in future studies and the use of anlotinib and immuneenhancing therapy, which is similar to other assessments of TKI in this field15.

    Another notable result in our study was the elevated TSH levels and changes in metabolic parameters (including blood triglyceride and blood glucose levels) caused by anlotinib,which may be predictors of good prognosis, and elevated blood triglyceride levels protected both PFS and OS from the risk factors. Although such adverse events in the trial seldom reached grade III (3.06%, 0%), they covered a broad range.That is, the incidence rate of hypertriglyceridemia was 44.56% in the anlotinib group. However, it was only 23.78% in the placebo group. The incidence rates of hypercholesterolemia were 41.84% and 13.99%, respectively,and those of hyper-low density lipoproteinemia were 21.09%and 7.69%, respectively. However, the impact of small molecule targeted therapy on the endocrine system and fat metabolism are less assessed, and the results are usually contradictory. For instance, Ho et al.16have found that the levels of polyunsaturated fatty acids were elevated in patients with EGFR mutations, whereas reduced proportion of polyunsaturated fatty acids in the membrane phospholipids induced by inhibitors also lowered the activity of the EGFR membrane receptors, which shows a synergistic effect with gefitinib17. Other studies have also found that the mammalian target of sirolimus, which is a rapamycin(mTOR) inhibitor, increased the blood levels of total cholesterol and triglycerides18,19. Further studies have revealed that such result might be attributed to the fact that sirolimus reduced the activity of post-heparin lipoprotein lipase, which is the primary enzyme responsible for triglyceride metabolism, and this induces hypertriglyceridemia20. This result indicated that patients may often require adjuvant therapy with lipid-lowering drugs and that several indicators of lipid metabolism may be effective markers of small molecular targeted drugs. Future studies should focus on assessing the effects of anlotinib on the endocrine system and its subsequent potential effect on the immune and hematopoietic systems to identify the possible predictors of efficacy and prognosis. Yang et al.21from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Science have found that the inhibition of cholesterol esterification could enhance the antitumor activity of CD8+T cells (also known as killer T cells), indicating that such studies are strongly recommended.

    In conclusion, anlotinib plays a dual role as an antitumor and antiangiogenic agent. Its broad target range can help overcome the acquired resistance induced by multiple chemotherapies/targeted treatments. However, it is also more susceptible to interactions with the patient’s internal environment than mono-targeted agents. Factors, including tumor burden, gene characteristics, as well as a patient’s immune, endocrine, and metabolic status, may also affect the efficacy and prognosis of anlotinib treatment. Further indepth studies must be conducted to identify the reliable markers of efficacy and prognosis.

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    亚洲片人在线观看| 天天躁日日躁夜夜躁夜夜| 久久精品国产99精品国产亚洲性色 | 欧美成人午夜精品| 欧美成人午夜精品| 999久久久国产精品视频| 日韩欧美一区二区三区在线观看 | 亚洲成国产人片在线观看| 免费av中文字幕在线| 丁香六月欧美| 99国产精品一区二区三区| 老司机亚洲免费影院| 天堂俺去俺来也www色官网| 欧美日韩亚洲高清精品| 天天影视国产精品| 日韩欧美一区二区三区在线观看 | 91国产中文字幕| 欧美日韩福利视频一区二区| 在线观看日韩欧美| 真人做人爱边吃奶动态| 新久久久久国产一级毛片| 90打野战视频偷拍视频| aaaaa片日本免费| 99国产精品99久久久久| 精品人妻1区二区| 美女高潮到喷水免费观看| 久久九九热精品免费| 久久影院123| 亚洲专区字幕在线| 丝袜在线中文字幕| 国产在线一区二区三区精| 涩涩av久久男人的天堂| 深夜精品福利| av超薄肉色丝袜交足视频| 国产av又大| 多毛熟女@视频| 亚洲成人手机| 三上悠亚av全集在线观看| 欧美黄色片欧美黄色片| 日韩三级视频一区二区三区| 最近最新免费中文字幕在线| 久久久久久亚洲精品国产蜜桃av| 国产精品一区二区免费欧美| 久久精品亚洲熟妇少妇任你| 黄色成人免费大全| 国产精品亚洲一级av第二区| 精品国产亚洲在线| 一二三四社区在线视频社区8| a在线观看视频网站| 成人影院久久| 老司机靠b影院| 亚洲第一av免费看| 久久亚洲精品不卡| 一进一出好大好爽视频| 90打野战视频偷拍视频| 一边摸一边抽搐一进一小说 | av电影中文网址| 精品一区二区三区视频在线观看免费 | 人人妻人人澡人人看| 两个人看的免费小视频| 欧美精品亚洲一区二区| 女人高潮潮喷娇喘18禁视频| 日韩欧美一区二区三区在线观看 | 欧美黄色淫秽网站| 久久人人爽av亚洲精品天堂| 真人做人爱边吃奶动态| 色婷婷久久久亚洲欧美| 午夜视频精品福利| 在线观看免费视频网站a站| 国产精品.久久久| 婷婷精品国产亚洲av在线 | 亚洲精品美女久久久久99蜜臀| 12—13女人毛片做爰片一| 国产成人精品久久二区二区免费| 精品久久久精品久久久| 女警被强在线播放| 午夜免费观看网址| 国产无遮挡羞羞视频在线观看| 午夜免费鲁丝| 欧美精品亚洲一区二区| 99国产极品粉嫩在线观看| 建设人人有责人人尽责人人享有的| 动漫黄色视频在线观看| 日本五十路高清| 一级a爱视频在线免费观看| 天天躁夜夜躁狠狠躁躁| 国产欧美日韩一区二区三| 巨乳人妻的诱惑在线观看| 高清视频免费观看一区二区| 亚洲av欧美aⅴ国产| 久久久国产精品麻豆| 久久精品国产亚洲av香蕉五月 | 免费久久久久久久精品成人欧美视频| 精品久久久久久久久久免费视频 | 国产国语露脸激情在线看| 久久午夜综合久久蜜桃| 黑人操中国人逼视频| 久久久久国产精品人妻aⅴ院 | a在线观看视频网站| 黑丝袜美女国产一区| 午夜福利乱码中文字幕| 精品福利观看| 国产精品久久电影中文字幕 | 在线观看日韩欧美| 亚洲熟妇熟女久久| 少妇粗大呻吟视频| 啦啦啦视频在线资源免费观看| 欧美色视频一区免费| 午夜免费观看网址| 久久久久久免费高清国产稀缺| 久久国产精品人妻蜜桃| 黄片大片在线免费观看| 午夜福利,免费看| 精品国产超薄肉色丝袜足j| 久久热在线av| 香蕉国产在线看| 十八禁网站免费在线| 每晚都被弄得嗷嗷叫到高潮| 99国产精品99久久久久| 色婷婷av一区二区三区视频| 99精国产麻豆久久婷婷| 午夜影院日韩av| 又黄又爽又免费观看的视频| 美女扒开内裤让男人捅视频| 色精品久久人妻99蜜桃| 欧美午夜高清在线| 超碰97精品在线观看| 丁香六月欧美| 最新在线观看一区二区三区| 亚洲国产精品一区二区三区在线| 一a级毛片在线观看| 黑人巨大精品欧美一区二区mp4| 国产人伦9x9x在线观看| 国产av又大| 久久精品人人爽人人爽视色| 亚洲美女黄片视频| 一边摸一边抽搐一进一出视频| 国产精品欧美亚洲77777| 99久久国产精品久久久| 亚洲av日韩在线播放| 他把我摸到了高潮在线观看| 日韩中文字幕欧美一区二区| 一级毛片女人18水好多| 视频区图区小说| 香蕉丝袜av| 久久久精品免费免费高清| 国产精品亚洲一级av第二区| 久久青草综合色| 极品人妻少妇av视频| 亚洲国产精品一区二区三区在线| 国产免费av片在线观看野外av| 建设人人有责人人尽责人人享有的| 亚洲 欧美一区二区三区| 91在线观看av| 老司机亚洲免费影院| 悠悠久久av| 一本综合久久免费| 99久久综合精品五月天人人| 国产成人影院久久av| 久久久久久久午夜电影 | 国产视频一区二区在线看| 50天的宝宝边吃奶边哭怎么回事| 黄色片一级片一级黄色片| 欧美日韩乱码在线| 久久精品国产亚洲av香蕉五月 | 国产成人精品无人区| 黄片小视频在线播放| 自线自在国产av| 欧美激情久久久久久爽电影 | 亚洲 国产 在线| 亚洲国产精品合色在线| 亚洲在线自拍视频| 久久久精品国产亚洲av高清涩受| 满18在线观看网站| 深夜精品福利| 天天躁狠狠躁夜夜躁狠狠躁| 亚洲欧美激情在线| 99久久99久久久精品蜜桃| 成人18禁在线播放| 性少妇av在线| netflix在线观看网站| 日日夜夜操网爽| 成熟少妇高潮喷水视频| 操出白浆在线播放| 国内久久婷婷六月综合欲色啪| 多毛熟女@视频| 在线十欧美十亚洲十日本专区| 国产男靠女视频免费网站| 久久久水蜜桃国产精品网| 国产欧美日韩综合在线一区二区| 精品高清国产在线一区| 日韩成人在线观看一区二区三区| 90打野战视频偷拍视频| 成年女人毛片免费观看观看9 | 日本欧美视频一区| 俄罗斯特黄特色一大片| 一级片'在线观看视频| 亚洲专区字幕在线| 老汉色∧v一级毛片| 亚洲少妇的诱惑av| 欧美在线黄色| 亚洲国产看品久久| 黄色女人牲交| 男女免费视频国产| 一区二区三区精品91| 午夜成年电影在线免费观看| 9191精品国产免费久久| 午夜福利一区二区在线看| 欧美人与性动交α欧美精品济南到| 咕卡用的链子| tube8黄色片| 捣出白浆h1v1| videos熟女内射| 成人亚洲精品一区在线观看| tocl精华| 高潮久久久久久久久久久不卡| 在线十欧美十亚洲十日本专区| 91成人精品电影| 国产一区二区三区综合在线观看| 在线观看免费日韩欧美大片| 久久影院123| 在线观看www视频免费| 亚洲av美国av| 国产精华一区二区三区| 夜夜躁狠狠躁天天躁| 身体一侧抽搐| 亚洲精品国产精品久久久不卡| 国产极品粉嫩免费观看在线| 中文字幕av电影在线播放| 成人国产一区最新在线观看| 午夜福利在线免费观看网站| 很黄的视频免费| netflix在线观看网站| 天天躁狠狠躁夜夜躁狠狠躁| 男女下面插进去视频免费观看| 免费av中文字幕在线| 亚洲精品一卡2卡三卡4卡5卡| 精品国产美女av久久久久小说| 亚洲人成电影免费在线| 女人爽到高潮嗷嗷叫在线视频| 亚洲全国av大片| 两个人免费观看高清视频| 精品电影一区二区在线| 色94色欧美一区二区| 三级毛片av免费| av电影中文网址| 乱人伦中国视频| 国产午夜精品久久久久久| 99久久精品国产亚洲精品| 超碰成人久久| 欧美黑人精品巨大| 久久九九热精品免费| 欧美大码av| 又紧又爽又黄一区二区| 99热只有精品国产| 国产熟女午夜一区二区三区| 男男h啪啪无遮挡| 精品亚洲成国产av| 在线看a的网站| www.精华液| 国产亚洲精品久久久久久毛片 | 国产精品偷伦视频观看了| 免费在线观看日本一区| 他把我摸到了高潮在线观看| 久久午夜亚洲精品久久| 亚洲情色 制服丝袜| 乱人伦中国视频| 青草久久国产| 国产亚洲精品久久久久久毛片 | 国产99白浆流出| 啪啪无遮挡十八禁网站| 久久精品亚洲精品国产色婷小说| 日韩视频一区二区在线观看| 亚洲中文日韩欧美视频| 国产精品.久久久| 人人澡人人妻人| av在线播放免费不卡| 久久久精品国产亚洲av高清涩受| 飞空精品影院首页| 国产欧美日韩一区二区精品| 成人特级黄色片久久久久久久| 国产亚洲精品久久久久5区| 久久 成人 亚洲| 欧美午夜高清在线| 黄色丝袜av网址大全| 一级a爱片免费观看的视频| 久99久视频精品免费| 黄色成人免费大全| 高清黄色对白视频在线免费看| 精品国内亚洲2022精品成人 | av片东京热男人的天堂| 嫩草影视91久久| 国产精品成人在线| 精品国产亚洲在线| 国产精品 国内视频| 高清欧美精品videossex| 女人久久www免费人成看片| 成年女人毛片免费观看观看9 | 亚洲熟女精品中文字幕| 动漫黄色视频在线观看| 成人手机av| a级毛片黄视频| 欧美激情高清一区二区三区| 色播在线永久视频| 国产一区二区三区在线臀色熟女 | 中文字幕制服av| 最新的欧美精品一区二区| 午夜福利影视在线免费观看| 国产高清激情床上av| cao死你这个sao货| 亚洲国产精品sss在线观看 | 热99国产精品久久久久久7| 国产成人欧美| 女性生殖器流出的白浆| 无人区码免费观看不卡| 国产成人精品久久二区二区免费| av在线播放免费不卡| 国产av又大| 又黄又粗又硬又大视频| 黄色女人牲交| 一级作爱视频免费观看| 一本综合久久免费| 一进一出好大好爽视频| 黄色片一级片一级黄色片| 9热在线视频观看99| 亚洲精品美女久久av网站| 欧美丝袜亚洲另类 | 一级a爱视频在线免费观看| 日韩三级视频一区二区三区| 99香蕉大伊视频| 午夜福利在线观看吧| 91大片在线观看| 亚洲精品中文字幕在线视频| 中文字幕人妻丝袜一区二区| 后天国语完整版免费观看| 国产精品一区二区免费欧美| 中文字幕制服av| 99国产综合亚洲精品| 中出人妻视频一区二区| 亚洲三区欧美一区| 成人亚洲精品一区在线观看| 欧美中文综合在线视频| 国产高清视频在线播放一区| 国产伦人伦偷精品视频| 久久影院123| 18禁观看日本| 国产成人精品久久二区二区91| 夜夜躁狠狠躁天天躁| 精品久久久久久,| 99riav亚洲国产免费| 韩国av一区二区三区四区| 国产在线观看jvid| 国产欧美日韩综合在线一区二区| ponron亚洲| 青草久久国产| 成人av一区二区三区在线看| 国产精品美女特级片免费视频播放器 | 国产免费现黄频在线看| 韩国av一区二区三区四区| 天天添夜夜摸| 两性午夜刺激爽爽歪歪视频在线观看 | 久久精品91无色码中文字幕| 久热爱精品视频在线9| 一级,二级,三级黄色视频| 老司机在亚洲福利影院| 丝袜人妻中文字幕| 亚洲精品国产区一区二| 国产欧美日韩综合在线一区二区| 人人妻,人人澡人人爽秒播| 很黄的视频免费| 欧美+亚洲+日韩+国产| 亚洲人成电影免费在线| 精品人妻1区二区| 精品一区二区三区四区五区乱码| 久久久久久人人人人人| 日本撒尿小便嘘嘘汇集6| av天堂在线播放| 国产成人免费观看mmmm| 欧美在线黄色| 亚洲精品国产色婷婷电影| 少妇被粗大的猛进出69影院| 欧美大码av| 深夜精品福利| 99国产精品99久久久久| 久久中文字幕一级| 美女国产高潮福利片在线看| 亚洲五月天丁香| 精品福利观看| 日韩大码丰满熟妇| 亚洲国产欧美日韩在线播放| 国产麻豆69| 免费看a级黄色片| 国产成人欧美在线观看 | 国产成人av激情在线播放| 捣出白浆h1v1| 黑人操中国人逼视频| 91av网站免费观看| 777久久人妻少妇嫩草av网站| 最近最新免费中文字幕在线| 在线观看www视频免费| 久久久国产成人免费| 欧美日韩亚洲高清精品| 免费不卡黄色视频| av在线播放免费不卡| 国内久久婷婷六月综合欲色啪| 亚洲精品一二三| 黄片播放在线免费| 19禁男女啪啪无遮挡网站| 热re99久久国产66热| 久久中文字幕人妻熟女| 成年版毛片免费区| 久久精品亚洲av国产电影网| 大型黄色视频在线免费观看| 欧美丝袜亚洲另类 | 又黄又爽又免费观看的视频| 在线观看午夜福利视频| 国产一区二区三区视频了| 免费在线观看黄色视频的| 日韩欧美国产一区二区入口| 91麻豆av在线| 欧美老熟妇乱子伦牲交| 国产精品电影一区二区三区 | 老熟妇乱子伦视频在线观看| 亚洲五月婷婷丁香| 久久人人97超碰香蕉20202| 久99久视频精品免费| av中文乱码字幕在线| 777米奇影视久久| 黄色女人牲交| 欧美最黄视频在线播放免费 | 精品福利永久在线观看| 激情视频va一区二区三区| 欧美人与性动交α欧美精品济南到| 国产深夜福利视频在线观看| 精品欧美一区二区三区在线| 亚洲精品一二三| 99精品在免费线老司机午夜| 日韩欧美免费精品| 一二三四在线观看免费中文在| 国产精华一区二区三区| 日韩欧美国产一区二区入口| 一级片'在线观看视频| 日韩欧美一区视频在线观看| 怎么达到女性高潮| 久久中文字幕一级| 久热爱精品视频在线9| tocl精华| 精品亚洲成国产av| 国产高清videossex| 亚洲精品美女久久av网站| 午夜91福利影院| cao死你这个sao货| 国产精品久久久久久精品古装| 久久久精品国产亚洲av高清涩受| 午夜福利欧美成人| 黄色a级毛片大全视频| 色94色欧美一区二区| 国产精品乱码一区二三区的特点 | 国产成人精品久久二区二区91| 一边摸一边做爽爽视频免费| 一本一本久久a久久精品综合妖精| 国产欧美日韩精品亚洲av| 国产精品偷伦视频观看了| 欧美国产精品va在线观看不卡| 国产免费现黄频在线看| 高潮久久久久久久久久久不卡| 午夜福利一区二区在线看| 国产单亲对白刺激| av中文乱码字幕在线| 国产成人av教育| 老熟妇仑乱视频hdxx| 国产精品偷伦视频观看了| 亚洲精品成人av观看孕妇| 大型av网站在线播放| 99国产精品一区二区三区| 免费观看人在逋| 99国产精品99久久久久| 亚洲精品国产精品久久久不卡| 高潮久久久久久久久久久不卡| a级片在线免费高清观看视频| 国产精品欧美亚洲77777| 日韩精品免费视频一区二区三区| 777米奇影视久久| 国产真人三级小视频在线观看| 777米奇影视久久| 宅男免费午夜| 中文字幕高清在线视频| 夜夜爽天天搞| 欧美 日韩 精品 国产| 首页视频小说图片口味搜索| 久久中文看片网| 亚洲国产欧美网| cao死你这个sao货| 一进一出抽搐gif免费好疼 | 亚洲 欧美一区二区三区| 中文字幕人妻丝袜制服| 日本黄色视频三级网站网址 | av视频免费观看在线观看| 日日夜夜操网爽| 日本a在线网址| 欧美成人午夜精品| 亚洲人成伊人成综合网2020| av欧美777| 免费在线观看日本一区| 亚洲av日韩在线播放| 国产一区二区三区视频了| 国产精品亚洲av一区麻豆| 欧美黑人精品巨大| 免费一级毛片在线播放高清视频 | 久久中文字幕人妻熟女| 国产精品亚洲一级av第二区| 性少妇av在线| 国产不卡av网站在线观看| 国产成人免费无遮挡视频| 久久99一区二区三区| 国产一区二区三区视频了| 亚洲成国产人片在线观看| 欧美午夜高清在线| 韩国av一区二区三区四区| 99riav亚洲国产免费| 午夜免费成人在线视频| 国产精品一区二区在线不卡| 亚洲人成77777在线视频| 又黄又爽又免费观看的视频| av福利片在线| 欧美黑人精品巨大| 在线国产一区二区在线| 在线观看午夜福利视频| 国产日韩欧美亚洲二区| 两个人看的免费小视频| 日韩欧美免费精品| 999久久久精品免费观看国产| 18禁裸乳无遮挡动漫免费视频| 午夜福利,免费看| 国产免费男女视频| 男人操女人黄网站| 99re在线观看精品视频| 啦啦啦视频在线资源免费观看| 久久久久久久精品吃奶| 天天躁夜夜躁狠狠躁躁| www.精华液| 欧美日韩中文字幕国产精品一区二区三区 | 一级片免费观看大全| 好男人电影高清在线观看| 免费av中文字幕在线| 人人妻人人澡人人爽人人夜夜| 在线观看66精品国产| 精品一区二区三区四区五区乱码| 国产欧美日韩一区二区三| 在线观看舔阴道视频| 最新的欧美精品一区二区| videos熟女内射| 精品第一国产精品| 一夜夜www| 国产精品久久久久久精品古装| 欧美一级毛片孕妇| 国产三级黄色录像| 亚洲欧美日韩另类电影网站| 99久久精品国产亚洲精品| 亚洲,欧美精品.| 国产亚洲精品一区二区www | 91成人精品电影| 淫妇啪啪啪对白视频| 国产成人精品无人区| 91字幕亚洲| 国产高清国产精品国产三级| 欧美日韩乱码在线| 一进一出抽搐gif免费好疼 | 亚洲中文字幕日韩| 欧美一级毛片孕妇| 日韩熟女老妇一区二区性免费视频| 少妇 在线观看| 女人精品久久久久毛片| 亚洲av美国av| 国产精品国产高清国产av | 国产主播在线观看一区二区| 亚洲av片天天在线观看| 91国产中文字幕| 午夜福利欧美成人| 午夜日韩欧美国产| 久久精品亚洲av国产电影网| 国产真人三级小视频在线观看| 久久 成人 亚洲| 18禁裸乳无遮挡免费网站照片 | 日韩一卡2卡3卡4卡2021年| 在线免费观看的www视频| 女性被躁到高潮视频| 18禁黄网站禁片午夜丰满| 亚洲精品一二三| 热99国产精品久久久久久7| 日本一区二区免费在线视频| 亚洲精品一二三| 在线十欧美十亚洲十日本专区| 视频区图区小说| 久久中文看片网| 色老头精品视频在线观看| 免费在线观看亚洲国产| 亚洲久久久国产精品| 国产精品99久久99久久久不卡| e午夜精品久久久久久久| 亚洲成av片中文字幕在线观看| 老司机在亚洲福利影院| 亚洲免费av在线视频| 在线天堂中文资源库| 久久精品亚洲熟妇少妇任你| 亚洲一卡2卡3卡4卡5卡精品中文| 另类亚洲欧美激情| 欧美国产精品va在线观看不卡| 国产成人一区二区三区免费视频网站| 亚洲成人国产一区在线观看| 女人爽到高潮嗷嗷叫在线视频| 午夜精品久久久久久毛片777| av视频免费观看在线观看| 超碰成人久久| 日本wwww免费看|